title: [Intravenous gentamicin therapy in bilateral Menière disease].
abstract: BACKGROUND
  The treatment of severe forms of bilateral Menière's disease remains an especially challenging task. Similar problems also occur in debilitating Menière's disease in the only hearing ear. The intramuscular titration therapy with streptomycin has been the means of choice since 1984 to minimize the risk of total hearing loss in cases of severe bilateral disease.
  
  
  METHODS
  Since 1989 we have treated six out of 21 cases of bilateral Menière's disease by intravenous application of 2 x 120 mg gentamicin in Ringer's solution for several days. Additionally we reported on two cases in 1988. Only minor amounts of gentamicin were applied to sedate the function of both vestibular organs while avoiding damage to the cochlea.
  
  
  RESULTS
  In two cases hearing approved approximately about 10 dB, in two cases hearing remained stable, and in two cases hearing worsened about 10 dB. Five of six patients showed minor excitability in caloric tests on both sides, they did not complain of vertigo attacks one to five years after therapy.
  
  
  CONCLUSIONS
  Given that only very small amounts of gentamicin are applied to sedate the function of the vestibular organ while causing almost no damage to the cochlea, this method seems to be an excellent means for treatment of bilateral Menière's disease. Patients do not experience severe problems with equilibrium afterwards, and the treatment can be repeated as often as necessary.
authors.affiliation: Universitäts-Hals-Nasen-Ohrenklinik Essen.
authors.forename: K
authors.initials: K
authors.lastname: Jahnke
authors.forename: D
authors.initials: D
authors.lastname: Arweiler
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001309:Auditory Threshold / Q000187:drug effects; D002150:Caloric Tests; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects; D006312:Hearing Loss, Bilateral / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy* / Q000209:etiology; D008875:Middle Aged
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins